初诊超重和肥胖2型糖尿病患者采用利拉鲁肽结合短期胰岛素强化治疗的效果研究

Effect of Lilalutide Combined with Short-term Intensive Insulin Therapy on Newly Diagnosed Overweight and Obese Type 2 diabetes Patients

分析利拉鲁肽结合短期胰岛素强化治疗初诊超重和肥胖2型糖尿病患者的效果。选取2021年1月—2023年6月医院收治的60例初诊超重和肥胖2型糖尿病患者为研究对象,采用随机数字表法将其分为对照组和观察组两组,每组各30例。对照组实施短期胰岛素治疗,观察组在对照组的基础上联用利拉鲁肽治疗,对比两组患者治疗效果。结果显示,观察组患者BMI、腰围、体重测定结果均优于对照组(P<0.05);观察组患者空腹血糖、餐后2 h血糖水平、胰岛素抵抗指数、胰岛素用量均低于对照组,胰岛素分泌指数高于对照组(P<0.05);观察组患者各项脂肪因子水平均优于对照组(P<0.05);两组患者不良反应发生率比较,无统计学差异(P>0.05);除了物质生活功能评分,观察组其他各项生活质量指标评分均高于对照组(P<0.05)。研究发现,针对初诊超重和肥胖2型糖尿病患者,联合应用利拉鲁肽与短期胰岛素强化治疗可强化降糖效果,降低患者的血脂水平,减轻患者的体重,且治疗安全性较高。

To analyze the effect of Lilalutide combined with short-term intensive insulin therapy on newly diagnosed overweight and obese type 2 diabetes patients.60 newly diagnosed overweight and obese type 2 diabetes patients admitted to the hospital from January 2021 to June 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 30 cases in each group.The control group received short-term insulin therapy,while the obser-vation group received combination therapy with liraglutide on the basis of the control group.The treatment effects of the two groups of patients were compared.The results showed that the BMI,waist circumference,and weight measurement results of the observati-on group were better than those of the control group(P<0.05);The fasting blood glucose,2-hour postprandial blood glucose levels,insulin resistance index,and insulin dosage of the observation group were all lower than those of the control group,while the insulin secretion index was higher than that of the control group(P<0.05);The levels of various adipokines in the observation group were superior to those in the control group(P<0.05);There was no statistically significant difference in the incidence of adverse reac-tions between the two groups of patients(P>0.05);Except for the score of material life function,the scores of other quality of life indicators in the observation group were higher than those in the control group(P<0.05).The study found that,for newly diagnosed overweight and obese type 2 diabetes patients,the combination of rilalutide and short-term intensive insulin treatment can enhance the hypoglycemic effect,reduce the blood lipid level of patients,reduce the weight of patients,and have high treatment safety.